CardieX Limited announced sales results for the first quarter September 2023. In the September quarter the Company has recorded unaudited revenue of $1.36 million (compared to $0.56 million in first quarter of fiscal year 2022), which is a year-on-year growth of 143% across Company's traditional business, with the sales and lease of Company's XCEL and Oscar 2 devices to pharmaceutical companies, research institutions, and specialist clinicians.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.056 AUD | +5.66% | -21.13% | -58.52% |
Apr. 02 | Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes | MT |
Apr. 02 | Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-58.52% | 10.12M | |
+8.17% | 217B | |
+6.34% | 183B | |
+10.99% | 131B | |
+24.76% | 106B | |
-0.95% | 62.16B | |
+10.74% | 51.02B | |
+4.81% | 50.89B | |
-0.39% | 40.16B | |
+1.38% | 34.79B |
- Stock Market
- Equities
- CDX Stock
- News CardieX Limited
- CardieX Limited Announces Sales Results for the First Quarter September 2023